Compare The Coca-Cola Co K (KO) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Coca-Cola Co K vs Pfizer Inc — how do they compare? The Coca-Cola Co K trades at $88.39 (market cap $377.63B), while Pfizer Inc trades at $28.21 (market cap $158.56B). The key difference: The Coca-Cola Co K is far larger — about 2.4× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold The Coca-Cola Co K for 154 Days and Pfizer Inc for 158 Days on average.
| KO | PFE | |
|---|---|---|
Market Cap | $377.63B | $158.56B |
Volume | 14,894,568 | 44,138,282 |
Sector | Consumer Staples | Health |
52-Week High | $91.99 | $29.02 |
52-Week Low | $66.37 | $23.67 |
Typical Hold Time | 154 Days | 158 Days |
Enterprise Value | $404.81B | $210.06B |
Dividend Yield | 2.42% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coca-Cola (KO) trades at $87.97, up 2.51% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong profitability with a 28.56% net income margin and a 44.23% ROE for 2025. Analyst consensus is a Buy with a $95.75 price target, and institutional buying activity is evident in recent news. The stock is positioned near key resistance at $88, with support at $87.
The outlook for KO is positive, driven by consistent earnings performance and a strong dividend history, but risks include high valuation multiples and regional demand volatility. The stock offers stability with growth potential, though investors should monitor debt levels and competitive pressures in the beverage industry.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
